» Articles » PMID: 37696982

Acoustically Targeted Noninvasive Gene Therapy in Large Brain Volumes

Overview
Journal Gene Ther
Date 2023 Sep 11
PMID 37696982
Authors
Affiliations
Soon will be listed here.
Abstract

Focused Ultrasound Blood-Brain Barrier Opening (FUS-BBBO) can deliver adeno-associated viral vectors (AAVs) to treat genetic disorders of the brain. However, such disorders often affect large brain regions. Moreover, the applicability of FUS-BBBO in the treatment of brain-wide genetic disorders has not yet been evaluated. Herein, we evaluated the transduction efficiency and safety of opening up to 105 sites simultaneously. Increasing the number of targeted sites increased gene delivery efficiency at each site. We achieved transduction of up to 60% of brain cells with comparable efficiency in the majority of the brain regions. Furthermore, gene delivery with FUS-BBBO was safe even when all 105 sites were targeted simultaneously without negative effects on animal weight or neuronal loss. To evaluate the application of multi-site FUS-BBBO for gene therapy, we used it for gene editing using the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 (Cas9) system and found effective gene editing, but also a loss of neurons at the targeted sites. Overall, this study provides a brain-wide map of transduction efficiency, shows the synergistic effect of multi-site targeting on transduction efficiency, and is the first example of large brain volume gene editing after noninvasive gene delivery with FUS-BBBO.

Citing Articles

Acoustically targeted measurement of transgene expression in the brain.

Seo J, Trippett J, Huang Z, Lee S, Nouraein S, Wang R Sci Adv. 2024; 10(32):eadj7686.

PMID: 39110811 PMC: 11305388. DOI: 10.1126/sciadv.adj7686.


Plate-Based High-Throughput Fluorescence Assay for Assessing Enveloped Virus Integrity.

Macleod S, Super E, Batt L, Yates E, Jones S Biomacromolecules. 2024; 25(8):4925-4933.

PMID: 39040021 PMC: 11323024. DOI: 10.1021/acs.biomac.4c00358.


Adeno-associated virus vector delivery to the brain: Technology advancements and clinical applications.

Ye D, Chukwu C, Yang Y, Hu Z, Chen H Adv Drug Deliv Rev. 2024; 211:115363.

PMID: 38906479 PMC: 11892011. DOI: 10.1016/j.addr.2024.115363.


Engineering viral vectors for acoustically targeted gene delivery.

Li H, Harb M, Heath J, Trippett J, Shapiro M, Szablowski J Nat Commun. 2024; 15(1):4924.

PMID: 38858354 PMC: 11164914. DOI: 10.1038/s41467-024-48974-y.

References
1.
Turner T, Zourray C, Schorge S, Lignani G . Recent advances in gene therapy for neurodevelopmental disorders with epilepsy. J Neurochem. 2020; 157(2):229-262. PMC: 8436749. DOI: 10.1111/jnc.15168. View

2.
Simonato M, Bennett J, Boulis N, Castro M, Fink D, Goins W . Progress in gene therapy for neurological disorders. Nat Rev Neurol. 2013; 9(5):277-91. PMC: 3908892. DOI: 10.1038/nrneurol.2013.56. View

3.
Joshi C, Labhasetwar V, Ghorpade A . Destination Brain: the Past, Present, and Future of Therapeutic Gene Delivery. J Neuroimmune Pharmacol. 2017; 12(1):51-83. PMC: 5393046. DOI: 10.1007/s11481-016-9724-3. View

4.
Keeler G, Kumar S, Palaschak B, Silverberg E, Markusic D, Jones N . Gene Therapy-Induced Antigen-Specific Tregs Inhibit Neuro-inflammation and Reverse Disease in a Mouse Model of Multiple Sclerosis. Mol Ther. 2017; 26(1):173-183. PMC: 5762980. DOI: 10.1016/j.ymthe.2017.09.001. View

5.
Spronck E, Brouwers C, Valles A, de Haan M, Petry H, van Deventer S . AAV5-miHTT Gene Therapy Demonstrates Sustained Huntingtin Lowering and Functional Improvement in Huntington Disease Mouse Models. Mol Ther Methods Clin Dev. 2019; 13:334-343. PMC: 6446047. DOI: 10.1016/j.omtm.2019.03.002. View